PositiveID Corporation Files U.S. Patent for Its Firefly Dx Real-Time PCR System

DELRAY BEACH, Fla., March 4, 2015 (GLOBE NEWSWIRE) — PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a developer of biological detection and diagnostics solutions, today announced that it has filed a new U.S. patent for its Firefly Dx real-time PCR (polymerase chain reaction) pathogen detection system. The patent filing, A Cyclical and Continuous Flow PCR Device, covers a cyclical mechanism of thermal cycling required to complete real-time PCR and deliver results in less than 20 minutes. This brings the Company’s total number of patents and patents pending to 17.

Firefly Dx is designed to provide real-time, accurate diagnostic results in a handheld device, thereby leading to treatment scenarios at the point of need that are not possible with existing systems, which require lab-based equipment and can take hours or even days to provide results. Firefly Dx is targeting the global PCR market, which is projected to reach approximately $27.4 billion this year, according to a Research and Markets’ report Polymerase Chain Reaction (PCR) – Products/Tools – A Global Market Watch, 2009-2015. Firefly’s applications include point of need monitoring of pathogenic outbreaks (such as Ebola, influenza, etc.), agricultural screening in both domestic sectors and developing countries, and for the detection of biological agents associated with weapons of mass destruction.

Source: globenewswire.com

See on Scoop.itBiodefense News

BVTI aims to hire interagency biodefense analyst

Best Value Technology (BVTI) said in a recent job posting that it is seeking an interagency biodefense analyst.

This position acts as a support person for interagency coordination with biodefense assessment, prioritization efforts and risk-reduction activity in the field of homeland security. An interagency analyst will assist in assessments of capabilities in biodefense methods and coordinates the interagency interfaces during these assessments. The analyst also will evaluate models of assessments to make improvements to the methodologies of identifying risks and will review the quality of data and other outcomes. This analyst also will be expected to support recommendations on prioritization of risk reduction across the solution space.

Source: bioprepwatch.com

See on Scoop.itBiodefense News